¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"manual visual method"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • visual confusion
    ½Ã°¢È¥¶õ
  • visual cortex
    ½Ã°¢°ÑÁú, ½Ã(°¢)ÇÇÁú
  • visual defect
    ½Ã(°¢)°á¼Õ
  • visual deprivation
    ½Ã°¢¹ÚÅ»
  • visual discrimination
    ½Ã°¢½Äº°
  • visual disturbance
    ½Ã·ÂÀå¾Ö, ½Ã°¢Àå¾Ö
  • visual efficiency
    ½Ã(°¢)È¿À²
  • visual evoked potential
    ½Ã°¢À¯¹ßÀüÀ§
  • visual evoked response
    ½Ã°¢À¯¹ß¹ÝÀÀ
  • visual field
    ½Ã¾ß
  • visual field defect
    ½Ã¾ß°á¼Õ
  • visual field examination
    ½Ã¾ß°Ë»ç
  • visual hallucination
    ȯ½Ã
  • visual image
    ½Ã°¢»ó
  • visual infancy
    ¿µ¾ÆÇü½Ã°¢
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • visual discrimination
    ½Ã°¢½Äº°
  • visual disturbance
    ½Ã·ÂÀå¾Ö, ½Ã°¢Àå¾Ö
  • visual field defect
    ½Ã¾ß°á¼Õ
  • visual efficiency
    ½Ã°¢È¿À²
  • visual field examination
    ½Ã¾ß°Ë»ç
  • kinetic visual field
    µ¿Àû½Ã¾ß
  • static visual field
    Á¤Àû½Ã¾ß
  • visual field
    ½Ã¾ß
  • visual hallucination
    ȯ½Ã, º¸ÀÓȯ°¢
  • visual image
    ½Ã°¢»ó
  • visual infancy
    ¿µ¾ÆÇü½Ã°¢
  • organic visual loss
    ±âÁú½Ã°¢»ó½Ç
  • visual line
    ½Ã°¢¼±
  • visual maturity
    ¼º¼÷½Ã°¢
  • visual memory
    ½Ã°¢±â¾ï
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Octoson scanning method
    ¿ÁÅä¼Õ ½ºÄµ¹ý (Ûö)
  • Proetz displacement method
    ÇÁ·ÚÃ÷ġȯ¹ý
  • Quellung method
    ÆØÃ¢¹ý(ø³óìÛö).
  • Quellung method
    ÆØÃ¢¹ý(ø³óìÛö).
  • Rothera method
    ·ÎÅ×¶ó¹ý
  • Schoenheimer-Sperry method
    ½¨ÇÏÀ̸Ó-½ºÆä¸® ¹æ¹ý
  • Shihabi-Bishop method
    ½ÃÇϺñ-ºñ¼ó ¹æ¹ý
  • Spinner method
    ½ºÇdzÊ(¹æ)¹ý
  • Tietz-Fiereck method
    ƼÂÅ-ÇÇ·º¹æ¹ý
  • Valsalva method
    ¹ß»ì¹Ù¹ý
  • Wintrobe hematocrit method
    À©Æ®·ÎºêÇ츶ÅäÅ©¸®Æ®¹ý
  • Zebra-stripe imaging method
    ¾ó·è¸» ¹«´Ì ¿µ»ó ¹æ¹ý
  • Zeeman correction method
    Áö¸¸±³Á¤¹ý
  • acid hematin method
    »êÇ츶ƾ¹ý(¡­Ûö).
  • acquisition method
    ȹµæ ¹æ¹ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • retinal visual cells
    ¸Á¸·½Ã¼¼Æ÷
  • rivalry of visual fields
    ½Ã¾ß(ãÊå¯)°æÇÕ.
  • rivaly in the visual field
    ½Ã¾ß°æÇÕ
  • static visual field
    Á¤Àû½Ã¾ß
  • stereoscopic visual acuity
    ÀÔü½Ã·Â
  • visual
    ½Ã·Â(ãÊæ³)ÀÇ, ½Ã°¢(ãÊÊÆ)ÀÇ
  • visual
    ½Ã·Â(ãÊæ³)ÀÇ, ½Ã°¢(ãÊÊÆ)ÀÇ.
  • visual acuity
    ½Ã·Â(ãÊæ³)
  • visual acuity
    ½Ã·Â(ãÊæ³).
  • visual acuity test
    ½Ã·Â°Ë»ç(¡­ËþÞÛ)
  • visual acuity test
    ½Ã·Â°Ë»ç(¡­ËþÞÛ).
  • visual acuity test chart
    ½Ã·Â°Ë»çÇ¥, ½Ã½Ã·ÂÇ¥(ãËãÊæ³øú)
  • visual acuity test chart
    ½Ã½Ã·ÂÇ¥(ãËãÊæ³øú), ½Ã·Â°Ë»çÇ¥.
  • visual agnosia
    ½Ã°¢½ÇÀÎÁõ
  • visual agnosis
    ½Ã°¢½ÇÀÎ(ãÊÊÆã÷ìã).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Folch method
    ÆúÃ÷¹ý(Ûö)
  • Folin method
    Æú¸°¹ý(Ûö)
  • Folin-Wu method
    Æú¸°-¿ì¹ý(Ûö)
  • gaseous exposure method
    °³½º ³ëÃâ¹ý(ÖÚõóÛö)
  • Gilbert-Maxam method
    ±æ¹öÆ®-¸Æ»ï¹ý(Ûö)
  • gradient-flow method
    ±¸¹è(ÎþÛÕ)-È帧¹ý(Ûö)
  • heavy atom method
    Áß¿øÀÚ¹ý(ñìê«í­Ûö)
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • isotope derivative method
    µ¿À§¿ø¼ÒÀ¯µµÃ¼¹ý(ÔÒêÈêªáÈë¯Óôô÷Ûö)
  • jump method
    ¶Ù±â ¹æ¹ý(Û°Ûö)
  • Kjeldahl method
    Ű¿¤´Þ¹ý(Ûö)
  • label triangulation method
    Ç¥Áö»ï°¢È­¹ý(øöò½ß²ÊÇûùÛö)
  • Lowry method
    ·Î¿ì¸®¹ý(Ûö)
  • low-temperature heat method
    Àú¿Â¿­¹ý(î¸è®æðÛö)
  • LTH method
    LTH¹ý(Ûö)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AMH Accreditation Manual for Hospitals; anti-mullerian hormone; automated medical history
CSM cardiosynchronous myostimulator; carotid sinus massage; cerebrospinal meningitis; circulation, sensa...
DSM dextrose solution mixture; Diagnostic and Statistical Manual [of Mental Disorders]; Diploma in Socia...
DSM-III-R Diagnostic and Statistical Manual of Mental Disorders [of APA], third edition, revised
DSM-IV Diagnostic and Statistical Manual of Mental Disorders [of APA], fourth edition
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CRM Continual Reassessment Method
FEM Finite Element Method
HPLC High-Performance Liquid Chromatographic method
LAM Lactational Amenorrhea Method
MEM Maximum Entropy Method
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Barber's method
    ¹Ù¾Æ¹ö ¹ý
    ¹Ì»ý¹°À» Çö¹Ì°æ¿¡¼­ ´Ü¸®ÇÏ´Â Á¶ÀÛ¹ý.
  • Barker's method
    ¹Ù¾ÆÄ¿¹ý
    Ƽ¿À½Ã¾È¿°°ú Á¦ 2Áú»ê öÀÇ È­ÇÕ¿¡ ÀÇÇÑ ºñ»ö¹ý.
  • bioassay method
    »ý¹°ÇÐÀû °ËÁ¤¹ý
  • candle jar method
    Ä­µé Àھƹý, Ä­µé ÀÚ¾Æ ¹è¾ç¹ý
  • carbol fuchsin method
    Ä«¸£º¼ Ǫũ½Å ¹ý
  • Charter's method
    Â÷ÅÍ ¹ý
    Ä©¼Ö »ç¿ë¹ýÀÇ Çϳª·Î, ¼ÖÀÌ Ä¡¾Æ¿Í Ä¡Àº¿¡ ´ëÇÏ¿© 45¡Æ·Î Ä¡°ü ÂÊÀ¸·Î ±â¿ï¾îÁö°Ô Çϸ鼭 ¼öÆòÀ» À¯Áö½ÃŰ°í ¼ÖÀÇ ¹ÝÀº Ä¡¾Æ¿¡ ±×¸®°í ¹ÝÀº Ä¡Àº¿¡ ÀÖµµ·Ï ÇÑ ´ÙÀ½, ¾ÆÁÖ ÀÛÀº ¿øÀ» ±×¸®´Â µíÇÑ Áøµ¿ ¿îµ¿À» Áָ鼭 ÇÏ´Â ¹æ¹ý. À½½Ä Â±â¿Í Ä¡°£¿¡ ¼ÖÀÌ µé¾î°¡°Ô µÇ¾î ¸¶»çÁö ¿ªÇÒµµ ÇÑ´Ù.
  • Chopper method
    Chopper ¹ý
  • column diffusion method
    ±âµÕ È®»ê ¹æ¹ý
  • combination method
    ¿¬ÇÕ¹ý
    Àη¹À̳ª Ä¡°ü º¸Ã¶ Á¦ÀÛ¿¡¼­ ¸ðÇü»ó¿¡ ³³ÇüÀ» ÀÏÂ÷·Î ¿Ï¼ºÇÏ¿© ±¸°­³»¿¡ ½ÃÀûÇÏ¿© ½Ã°øÇÏ°í ¸Å¸ôÇÏ¿© ÁÖÁ¶ÇÏ¿© ¾ò´Â °£Á¢¹ý°ú Á÷Á¢¹ýÀ» °â¿ëÇÏ´Â ¹æ¹ýÀÌ´Ù.
  • Dehn-Clark`s method
    µ§-Ŭ¶óÅ©¹ý
  • Denis-Leche's method
    µ¥´Ï½º-·¹Ä¡¹ý
    Àü Ȳȭ¹°ÀÇ °ËÃâ¹ýÀ¸·Î, »êÀ» °¡ÇØ ºÎÆÐÇÑ ´Ü¹éÁúÀ» Á¦°ÅÇÏ°í ¿°È­ ¹Ù·ý¿¡ ÀÇÇØ ħÀü °ÇÁ¶½ÃŲ ÈÄ Äª·®ÇÑ´Ù.
  • diffusion method
    È®»ê¹ý
  • direct method
    Á÷Á¢¹ý
    ȯÀÚÀÇ ±¸°­³»¿¡¼­ ¿Î½º Á¶°¢ÇÏ¿© ³³ ¿øÇüÀ» ¾ò¾î ¸Å¸ôÇϰí ÁÖÁ¶ÇÏ¿© Àη¹À̳ª Ä¡°ü º¸Ã¶¹°À» ¾ò´Â ¹æ¹ýÀÌ´Ù.
  • discomfort with this imaging method
    ÃÔ¿µ½Ã ºÒÆí°¨
  • double investing method
    ÀÌÁß ¸Å¸ô¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
visual pigments The photopigments in the retinal cones and rods that absorb light and initiate the visual process.
(05 Mar 2000)
visual projection A perceptual synthesis involving visual mechanisms.
(05 Mar 2000)
visual purple <protein> Light sensitive pigment formed from retinal linked through a Schiff's base to opsin: rhodopsin is an integral membrane protein found in the discs of retinal rods and cones, comprising some 40% of the membrane. Vertebrate opsins are proteins of 38 kD.
See: bacteriorhodopsin.
(18 Nov 1997)
visual receptor cells The rod and cone cell's of the retina.
(05 Mar 2000)
visual-spatial agnosia The inability to localise objects or to appreciate distance, motion, and spatial relationships; caused by lesion in the occipital lobe.
Compare: simultanagnosia.
(05 Mar 2000)
visual threshold Threshold of visual sensation, the minimal light intensity evoking a visual sensation.
Synonym: achromatic threshold, minimum light threshold.
(05 Mar 2000)
visual violet A visual pigment, composed of 11-cis-retinal bound to an opsin, found in the cones of the retina.
Synonym: visual violet.
Origin: G. Ion, violet, + ops, eye, + -in
(05 Mar 2000)
visual yellow The orange retinaldehyde resulting from the action of light on the rhodopsin of the retina, which converts the 11-cis-retinal component of the rhodopsin to all-trans-retinal plus opsin.
Synonym: trans-retinal, visual yellow.
(05 Mar 2000)
primary visual area Area of the occipital lobe concerned with vision.
(12 Dec 1998)
primary visual cortex See: visual cortex.
(05 Mar 2000)
secondary visual area Area of the occipital lobe concerned with vision.
(12 Dec 1998)
secondary visual cortex See: visual cortex.
(05 Mar 2000)
evoked potentials, visual The electric response evoked in the cerebral cortex by visual stimulation or stimulation of the visual pathways.
(12 Dec 1998)
unformed visual hallucination Hallucination composed of sparks, lights, or bursting spheres of light.
(05 Mar 2000)
formed visual hallucination <psychiatry> Hallucination composed of scenes, often landscapes.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á